Hot

Dr. Mary Jane Minkin, OB-GYN, Highlights Key Topics Addressed in Annual Visits for Women’s Health Month

Retrieved on: 
水曜日, 5月 29, 2024
Oncology, Health, Consumer, Women, Other Health, General Health, Intrauterine device, Patient, Hot, Hormone replacement therapy, Libido, HPV, Education, Cramp, Pleasure, Pregnancy, Anxiety, Cervical cancer, Bacteria, Breast cancer, Vagina, Infection, Vaginitis, PAP, Birth, Yale School of Medicine, MAP, Woman, Menstruation, Reproductive Sciences, Menopause, Personal lubricant, Pain, HRT, Quality of life, Condom, STI, Senior counsel, Birth control

, OB-GYN, Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine, is shedding light on frequently discussed topics during annual OB-GYN visits.

Key Points: 
  • , OB-GYN, Clinical Professor of Obstetrics, Gynecology, and Reproductive Sciences at Yale University School of Medicine, is shedding light on frequently discussed topics during annual OB-GYN visits.
  • Dr. Minkin, dedicated to women's health and education, emphasizes the importance of these routine check-ups for maintaining overall well-being.
  • “Annual appointments with your OB-GYN are essential for early detection of potential issues, such as cervical or breast cancer, menopause and for managing reproductive health.
  • Annual visits are crucial for routine screenings and preventive care, including Pap smears for cervical cancer, mammograms for breast cancer detection, and HPV vaccinations.

Global Hormone Replacement Therapy (HRT) Market Analysis 2024-2032 Featuring Abbott, Bayer, Eli Lilly & Co, Novartis, Novo Nordisk, Pfizer, Abbvie, Teva, Dr. Reddy's Laboratories - ResearchAndMarkets.com

Retrieved on: 
水曜日, 5月 29, 2024
Health, Pharmaceutical, Statistics, New Drug Application, Patient, Hot, Hormone replacement therapy, Prescription, Hormone, Ministry, Libido, Arena Pharmaceuticals, Akorn, MHLW, Disorder, Prevalence, FDA, American Thyroid Association, Economic development, Testosterone, Osteoporosis, Dermatology, Gastroenterology, Thyroid, Fertilisation, Cardiology, VMS, Incidence, Acquisition, Insight, Woman, NIH, Tablet, Data science, Menopause, HRT, Fezolinetant, Alfa, Pharmaceutical industry

The global Hormone Replacement Therapy market is projected to attain a value of US$ 35.86 Billion by 2032.

Key Points: 
  • The global Hormone Replacement Therapy market is projected to attain a value of US$ 35.86 Billion by 2032.
  • Ascendis Pharma A/S's drug SKYTROFA received market authorization in January 2022 for treating growth hormone disorders in children and adolescents.
  • The prevalence of hormonal imbalances and related disorders is increasing, leading to a rise in demand for hormone replacement therapy.
  • The US has the biggest market for Hormone Replacement Therapy, with rising utilization among patients over 35 years old.

Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause

Retrieved on: 
水曜日, 5月 22, 2024
Patient, Weight gain, Neuroscience, Safety, Health, MD, VMS, Hot, Woman, Fatigue, Menopause, Quality of life

These include vasomotor symptoms as well as weight gain, significant daytime fatigue and cognitive difficulties.”

Key Points: 
  • These include vasomotor symptoms as well as weight gain, significant daytime fatigue and cognitive difficulties.”
    NOE-PPM-201 is a Phase 2a open-label study that is designed to examine the safety and efficacy of NOE-115, a monoamine modulator, in patients with vasomotor symptoms due to menopause and assess additional associated non-VMS menopausal symptoms.
  • The trial will initially evaluate 30 women with moderate to severe VMS at 6 centers in the US.
  • She added, “there remains a significant need for innovative treatments that address the broader group of symptoms that women in the menopause transition struggle with.
  • NOE-115 may be a unique therapeutic option with the potential to target multiple moderate-to-severe CNS-mediated menopausal symptoms.”

Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause

Retrieved on: 
木曜日, 5月 16, 2024
Biotechnology, Other Health, Health, General Health, Women, Pharmaceutical, Other Science, Research, Consumer, Science, Clinical Trials, American College, Hot, Elinzanetant, Menopause, VMS, Sleep, Quality of life, ACOG

Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) associated with menopause compared to placebo.

Key Points: 
  • Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) associated with menopause compared to placebo.
  • Elinzanetant successfully met all four primary endpoints in both studies demonstrating statistically significant reductions in the frequency and severity of moderate to severe VMS from baseline to week 4 and 12 compared to placebo.
  • In this study, elinzanetant successfully met the primary endpoint demonstrating a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 12 compared to placebo.
  • Bayer will submit the data from the OASIS 1, 2 and 3 studies to health authorities for approval of marketing authorizations of elinzanetant for the treatment of moderate to severe VMS associated with menopause.

Hinge Health Integrates Movement-Based Menopause Support into its Digital Musculoskeletal Clinic

Retrieved on: 
火曜日, 5月 14, 2024
Biotechnology, Technology, Other Health, Health, General Health, Women, Pharmaceutical, Software, Hospitals, Consumer, Clinical Trials, Therapy, Bone density, Hot, Hormone replacement therapy, Education, Workforce, Exercise, Pelvic floor, MD, MSK, Movement, Woman, Menopause, Myalgia, Facial muscles

Hinge Health announced today the launch of movement-based menopause support tailored to individuals with musculoskeletal (MSK) and pelvic health conditions.

Key Points: 
  • Hinge Health announced today the launch of movement-based menopause support tailored to individuals with musculoskeletal (MSK) and pelvic health conditions.
  • For women who experience musculoskeletal and pelvic health issues, the decline in estrogen during menopause can not only worsen existing symptoms but also trigger new joint, muscle, and pelvic health issues.
  • "Regular physical activity can significantly reduce the frequency and severity of disruptive symptoms that occur with menopause,” said Tamara Grisales, MD, Urogynecologist, Hinge Health.
  • “By incorporating care for menopause, companies can retain employees, boost productivity, and achieve significant cost savings,” said Inessa Lurye, Head of Women’s Health, Hinge Health.

Knight Therapeutics Reports First Quarter 2024 Results

Retrieved on: 
木曜日, 5月 9, 2024
Knight, DLBCL, News, ITP, Health maintenance organization, Hot, Vaginal discharge, Depreciation, Thrombocytopenia, Stomach, Inventory, Collection, Trial of the century, ASCT, Lymphoma, Patient, Acquisition, VVA, IAS, Menopause, Lenalidomide, Absorption, Blue balls, Bookkeeping

Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.

Key Points: 
  • Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.
  • Accounts payable and accrued liabilities: As at March 31, 2024, accounts payable and accrued liabilities were $94,711, an increase of $4,094 or 5%.
  • Cash, cash equivalents and marketable securities: As at March 31, 2024, Knight had $181,859 in cash, cash equivalents and marketable securities, an increase of $20,034 or 12% compared to December 31, 2023.
  • Knight will host a conference call and audio webcast to discuss its first quarter ended March 31, 2024, today at 8:30 am ET.

Cummins, Verizon Business ink groundbreaking deal for combo Neutral Host + Private 5G network

Retrieved on: 
月曜日, 5月 6, 2024
Hot, Element, Private, CMI, Ericsson, Host, Engineering, Senior, Tablet, Headache, Neutral, Verizon Business, JEP, Architecture, Internet service provider

NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Verizon Business and Cummins Inc (NYSE: CMI) today announced an agreement to implement Verizon’s all-new Neutral Host Network product at Cummins’ Jamestown Engine Plant (JEP) in Lakewood, NY. The deal combines a Neutral Host Network with a Verizon Private 5G Network to cover distinct public-network and private-network use cases onsite at JEP. Cummins views the network’s technological capabilities as integral to enhancing operations across the site and improving the already best-in-class quality of the engines it produces for its customers.

Key Points: 
  • Verizon Business will provide Cummins with both a private 5G network and a neutral host network, providing cellular coverage for distinct private and public use cases at Cummins’ Jamestown Engine Plant.
  • Combined with a private network, enterprises can manage both business-critical connected operations (via the private 5G network) and conventional but strengthened public-network connectivity to phones and tablets (via neutral host network), where signals might otherwise be weak.
  • As “anchor tenant” for the carrier-agnostic neutral host network, Verizon is technical lead for network implementation, responsible for engineering, equipment and installation.
  • The deal combines a Neutral Host Network with a Verizon Private 5G Network to cover distinct public-network and private-network use cases onsite at JEP.

The Fresh Market Launches its New Hot & Fresh Neapolitan-Style Pizza, Elevating Your Pizza Experience!

Retrieved on: 
木曜日, 5月 9, 2024
Retail, Restaurant, Bar, Food, Beverage, Honey, Crave, Pizza, Taste, Pepe, Friends, Family, The Fresh Market, Market, Multimedia, Hot, Running, Food delivery

The Fresh Market has crafted the ultimate solution with our New Hot and Fresh Pizza™, designed to quench the cravings of pizza lovers, busy families, and discerning foodies alike.

Key Points: 
  • The Fresh Market has crafted the ultimate solution with our New Hot and Fresh Pizza™, designed to quench the cravings of pizza lovers, busy families, and discerning foodies alike.
  • into a resounding chorus of "Hot and Fresh Pizza from The Fresh Market night!"
  • The Fresh Market’s delivery partners are sweetening the deal to enjoy the new Hot and Fresh Pizza™ with introductory deals:
    Door Dash: 20% off the full basket when ordering a Hot & Fresh Pizza with Promo Code: TFMPIZZA.
  • We’re thrilled to invite our valued guests to savor this exceptional Hot & Fresh pizza, meticulously prepared with the finest fresh ingredients, right here at The Fresh Market."

ŌURA Announces Be the Expert in You Campaign to Promote Body Literacy for Women

Retrieved on: 
水曜日, 5月 1, 2024
Wearables, Mobile Technology, Technology, Women, Fitness & Nutrition, Biotechnology, Hardware, Health, Consumer, General Health, Flo, FDA, Clue, University, Menstrual cycle, Pregnancy, Hot, Hope, Motivation, Male, Natural Cycles, Partnership, Conference, Research, Human, Heart rate, Female, Physiology, Vogue, Expert, Luteal phase, Oura Health, Menopause, Multimedia, Migraine, Temperature, HRV, Algorithm, Organization, Sleep, Nursing

“For example, a recent survey found that one in four women do not understand their menstrual cycle.

Key Points: 
  • “For example, a recent survey found that one in four women do not understand their menstrual cycle.
  • The latest enhancement to Oura's period tracking feature, Cycle Insights , will provide members with even more details about their cycles.
  • Designing the Future of Wearable Tech for Women, by Women
    Oura is proud to have a strong group of women at the helm of these features, research studies, and partnerships.
  • Seeing my scores and Oura data has helped inform me what's happening to my body beyond my cycle.

Cleveland-Cliffs to Publish Monthly Hot Rolled Coil Spot Price

Retrieved on: 
金曜日, 4月 26, 2024
Automotive Manufacturing, Manufacturing, Steel, Engineering, Machine Tools, Metalworking & Metallurgy, Hot, Letter

Cleveland-Cliffs Inc. (NYSE: CLF) announced today that, in response to industry trends and feedback from customers, the Company will publish a “Cliffs Hot Rolled Market Price” via letter to all flat-rolled customers on a monthly basis.

Key Points: 
  • Cleveland-Cliffs Inc. (NYSE: CLF) announced today that, in response to industry trends and feedback from customers, the Company will publish a “Cliffs Hot Rolled Market Price” via letter to all flat-rolled customers on a monthly basis.
  • The price will be published in conjunction with the monthly opening of the Hot Rolled order book, and will be simultaneously published at https://www.clevelandcliffs.com/doing-business/ .
  • Cliffs may also update this price more frequently as market conditions necessitate.
  • As the largest producer of flat-rolled steel in North America, we felt it necessary to do the same to make sure our customers had the most timely and reliable pricing information.”
    The first Cliffs Hot Rolled Market Price will be published this morning, April 26, 2024, in conjunction with the June Hot Rolled order book opening.